Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26845500 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL31503047 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL26845492 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL26845493 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL40248 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL19228951 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL40148 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL193907 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL40286 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL40247 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119529815-A | Acidizing corrosion inhibitor, acidizing working solution, and preparation method and application thereof | 西安石油大学 | 2025-02-28 | — | — | CN | claimed |
| CN-113683780-B | Antiserum and low-cytotoxicity polyamino acid gene delivery carrier material with membrane penetrating activity and nucleus positioning function | 广州医科大学 | 2022-07-05 | — | — | CN | claimed |
| CN-113683780-A | Antiserum and low-cytotoxicity polyamino acid gene delivery carrier material with membrane penetrating activity and nucleus positioning function | 广州医科大学 | 2021-11-23 | — | — | CN | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4626547-A1 | NON PEPTIDERGIC AGONISTS OF OXYTOCIN RECEPTOR | Université de Strasbourg (FR) | 2025-10-08 | — | — | EP | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20110245287-A1 | Hybrid Opioid Compounds and Compositions | HOLADAY JOHN W | 2011-10-06 | — | — | US | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| US-20100221176-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221176-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221176-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010099273-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010099273-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-5264112-A | Acidic nickel baths containing 1-(2-sulfoethyl)-pyridiniumbetaine | ATOTECH DEUTSCHLAND GMBH (DE) | 1993-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885TSHR 3319/4885 |
| US-20100221176-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | RAB5IF, RPS27A, PSMA6 | MEN1 2279/4885KMT2A 3626/4885TSHR 2895/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | MEN1 3886/4885KMT2A 1067/4885TSHR 1630/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | MEN1 4186/4885KMT2A 928/4885TSHR 1673/4885 |
| US-20110245287-A1 | Hybrid Opioid Compounds and Compositions | OPRM1, OPRK1, OPRL1 | MEN1 4845/4885KMT2A 2721/4885TSHR 4379/4885 |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | CXCR4, SDF4, ITGB4 | MEN1 2980/4885KMT2A 1207/4885TSHR 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.